What are the deal making implications of the credit crunch? This discussion takes a look at the impact of market conditions on biotechs'/VCs'/large pharma's current business and future prospects, liquidity and availability of finance, the impact on pipelines, availability of suitable programmes for large and mid sized pharma and biotech and the impact on valuations on distressed and acquiring companies.